Related Experiment Videos

Defective Fas ligand production in lymphocytes from MS patients

B Macchi1, C Matteucci, U Nocentini

  • 1Departments of Neuroscience, University of Rome Tor Vergata, Via di Tor Vergata 135 00133 Rome, Italy.

Neuroreport
|December 14, 2001
PubMed

Insights

Multiple sclerosis patients show reduced Fas ligand (Fas-L) expression and release from lymphocytes. This impairment in Fas-L may affect the elimination of harmful autoreactive immune cells in multiple sclerosis.

Area of Science:

  • Immunology
  • Neuroscience

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • The Fas/Fas-ligand (Fas-L) pathway plays a critical role in immune cell apoptosis and regulation.

Purpose of the Study:

  • To investigate Fas ligand (Fas-L) levels in cells from multiple sclerosis (MS) patients.
  • To evaluate the expression and release of Fas-L in lymphocytes from MS patients with different disease courses compared to healthy donors.

Main Methods:

  • A cross-sectional study design was employed.
  • Peripheral blood mononuclear cells (PBMCs) from MS patients (relapsing-remitting and secondary-progressive) and healthy donors were stimulated with PHA.
  • Fas and Fas-L levels (membrane-bound and soluble) were measured.

Main Results:

  • Statistically significant decreased expression of Fas (p = 0.001) and release of Fas-L (p = 0.045) were observed in lymphocytes from MS patients compared to healthy controls.
  • Fas-L production levels were inversely and highly significantly correlated with Expanded Disability Status Scale (EDSS) scores in MS patients.

Conclusions:

  • Impaired Fas-L release in stimulated PBMCs from MS patients suggests a potential deficit in eliminating autoreactive T-cell clones in vivo.
  • These findings may indicate a novel mechanism contributing to the pathogenesis of multiple sclerosis.

Related Concept Videos